The U.S. Food and Drug Administration (FDA) has authorized the Hope Biosciences Stem Cell Research Foundation (HBSCRF) to conduct Phase II clinical trial for simultaneous allogeneic adipose-derived mesenchymal stem cells administered intravenously to treat Parkinson’s disease. HBSCRF is a non-profit research organization, and will be the first to conduct multiple trials investigating administering donor cells as well as the patient’s own cells to treat Parkinson’s. The trial consists of 60 participants that are both male and female between the ages of 45-80 years old, and is the second FDA-approved clinical trial conducted by HBSCRF.
Read more here.
More on: News Regulatory